Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Kronox Lab Sciences Ltd (KRONOX)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544187 NSE: KRONOX Chemicals | Small Cap | Kronox Lab Sciences Share Price
₹189.50 8.05 (4.44%)
As on 02-Sep'26 16:59
Kronox Lab Sciences Ltd (KRONOX)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544187 NSE: KRONOX Chemicals | Small Cap | Kronox Lab Sciences Share Price
₹189.50 8.05 (4.44%)
As on 02-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹703 Cr.
Current Price
₹189.5
52-Week Low / High
₹96 / 223
TTM EPS
₹7.7
TTM Sales
₹105 Cr.
Book Value per Share
₹33.3
P/E Ratio
24.61
Higher than its 5-year historical median
Industry PE
49.3
Price to Book (P/B)
5.70
Higher than its 5-year historical median
Price to Sales (P/S)
6.68
Higher than its 5-year historical median
EV/EBITDA
16.08
In line with its 5-year historical median
Dividend Yield
0.26%
Profitability Efficiency
Return on Equity (ROE)
26.82%
Outperforms industry median
Return on Capital Employed (ROCE)
36.00%
Outperforms industry median
Return on Assets (ROA)
24.53%
Operating Profit Margin
33.9%
Net Profit Margin
27.33%
Gross Profit Margin
38.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
1.03%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
3.44%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
8.6%
Asset Quality
Promoter Holding
74.21%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹86 Cr.
Equity
₹37.1 Cr.
Face Value
₹10
All Time Low / High
₹96.00 / 228.55
Check Before You Invest
Quality
Very GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is Kronox Lab Sciences Ltd a good quality company?
Kronox Lab Sciences Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Kronox Lab Sciences Ltd performance compare with that of its Peers?
Revenue growth of Kronox Lab Sciences Ltd vs industry peers?
Kronox Lab Sciences Ltd revenue CAGR is 10.14%, compared to the industry median CAGR of 7.77%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Kronox Lab Sciences Ltd?
Promoters hold 74.21% of the Kronox Lab Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Kronox Lab Sciences Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 12.66% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kronox Lab Sciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 50.7% | 55.3% | 51.6% | 51.5% | 43.8% | 36% | - |
| Value Creation Index ⓘ | 2.6 | 3.0 | 2.7 | 2.7 | 2.1 | 1.6 | - |
Growth Parameters ⓘ |
|||||||
| Sales ⓘ | 62.5 | 82.3 | 95.6 | 89.9 | 100 | 101 | 105 |
| Sales YoY Gr. | - | 31.7% | 16.2% | -6% | 11.5% | 1% | - |
| Adj EPS ⓘ | 2.5 | 3.4 | 4.2 | 5.7 | 6.8 | 7.3 | 7.7 |
| YoY Gr. | - | 39.4% | 23.6% | 34.7% | 19.3% | 6.8% | - |
| BVPS (₹) ⓘ | 6.9 | 10.3 | 12.1 | 17.9 | 24.3 | 31.3 | 33.3 |
| Adj Net Profit ⓘ | 9.6 | 13.4 | 15.7 | 21.2 | 25.3 | 27 | 29 |
| Cash Flow from Ops. ⓘ | 11.3 | 9 | 19.7 | 17.4 | 30.7 | 23.9 | - |
| Debt/CF from Ops. ⓘ | 0 | 0.1 | 0 | 0 | 0 | 0.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 10.1% | 1.9% | 1% | ||||
| Adj EPS ⓘ | NA | 24.2% | 19.7% | 6.8% | ||||
| BVPSⓘ | NA | 35.4% | 37.4% | 28.9% | ||||
| Share Price | - | - | - | 13.1% | ||||
Key Financial Parameters ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 35.8 | 39.9 | 37 | 38.2 | 32.3 | 26.2 | 23.9 |
| Op. Profit Mgn % ⓘ | 23.7 | 24 | 22.7 | 31.5 | 33.1 | 33.9 | 33.4 |
| Net Profit Mgn % ⓘ | 15.4 | 16.3 | 16.5 | 23.6 | 25.2 | 26.6 | 27.1 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 151 | 146 | 157 | 139 | 148 | 139 |
| Cash Conv. Cycle ⓘ | 0 | 69 | 70 | 67 | 58 | 62 | 122 |
Valuation of Kronox Lab Sciences - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Sales | 62 | 82 | 96 | 90 | 100 | 101 |
| Operating Expenses ⓘ + | 48 | 63 | 74 | 62 | 67 | 67 |
| Operating Profit ⓘ | 15 | 20 | 22 | 28 | 33 | 34 |
| Operating Profit Margin (%) | 23.7% | 23.9% | 22.7% | 31.5% | 33.1% | 33.9% |
| Other Income ⓘ + | 1 | 1 | 2 | 2 | 3 | 5 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 2 | 2 | 1 | 1 | 1 | 2 |
| Profit Before Tax ⓘ | 13 | 18 | 22 | 29 | 34 | 37 |
| Tax ⓘ | 3 | 5 | 6 | 7 | 9 | 10 |
| Profit After Tax | 10 | 14 | 16 | 21 | 25 | 28 |
| PAT Margin (%) | 15.6% | 16.6% | 17.2% | 23.8% | 25.4% | 27.3% |
| Adjusted EPS (₹) | 2.5 | 3.5 | 4.4 | 5.8 | 6.9 | 7.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 8.70% | 7.30% | 6.70% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 27 | 40 | 45 | 66 | 90 | 116 | |||||
| Debt + | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Trade Payables | 7 | 12 | 8 | 6 | 7 | 7 | |||||
| Others Liabilities ⓘ | 4 | 4 | 1 | 1 | 1 | 3 | |||||
| Total Liabilities ⓘ | 37 | 56 | 54 | 74 | 98 | 127 | |||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 9 | 11 | 16 | 26 | 28 | 29 | |||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 1 | 1 | |||||
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Inventories | 5 | 8 | 9 | 9 | 6 | 8 | |||||
| Trade Receivables | 15 | 26 | 19 | 18 | 20 | 21 | |||||
| Cash Equivalents | 2 | 3 | 4 | 4 | 37 | 49 | |||||
| Others Assets ⓘ | 5 | 9 | 7 | 16 | 7 | 19 | |||||
| Total Assets ⓘ | 37 | 56 | 54 | 74 | 98 | 127 | |||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 11 | 9 | 20 | 17 | 31 | 24 |
| Cash Flow From Investing Activity ⓘ + | -3 | -8 | -7 | -17 | -28 | -24 |
| Cash Flow From Financing Activity ⓘ + | -7 | -1 | -13 | 0 | -2 | -0 |
| Net Cash Flow ⓘ | 1 | 1 | -0 | 0 | 0 | -0 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 36.29 | 40.58 | 38.55 | 38.45 | 32.56 | 26.82 | ||||
| ROCE (%) | 50.71 | 55.32 | 51.63 | 51.52 | 43.82 | 36 | ||||
| Asset Turnover Ratio | 1.67 | 1.75 | 1.73 | 1.41 | 1.16 | 0.9 | ||||
| PAT to CFO Conversion(x) | 1.1 | 0.64 | 1.25 | 0.81 | 1.24 | 0.86 | ||||
| Working Capital Days | ||||||||||
| Receivable Days | 90.20 | 91.50 | 84.70 | 73.50 | 68.40 | 74.10 | ||||
| Inventory Days | 32.10 | 28.90 | 31.90 | 37.40 | 28.50 | 26.60 | ||||
| Payable Days | 69.50 | 69.60 | 64.30 | 56.50 | 50.40 | 54.30 | ||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Kronox Lab Sciences Ltd FAQs
The current trading price of Kronox Lab Sciences on 02-Sep-2026 16:59 is ₹189.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Sep-2026 the market cap of Kronox Lab Sciences stood at ₹703.1 Cr
The latest P/E ratio of Kronox Lab Sciences as of 01-Sep-2026 is 24.61.
The latest P/B ratio of Kronox Lab Sciences as of 01-Sep-2026 is 5.70.
The 52-week high of Kronox Lab Sciences is ₹222.9 and the 52-week low is ₹96.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kronox Lab Sciences is ₹105 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Kronox Lab Sciences Ltd is a good quality company.
The key valuation ratios of Kronox Lab Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Kronox Lab Sciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Kronox Lab Sciences Ltd
The company was incorporated on November 18, 2008 as 'Kronox Lab Sciences Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 18, 2008 issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the company was converted into a public limited company pursuant to a resolution passed by its shareholders at an extra-ordinary general meeting held on May 25, 2019 and a fresh certificate of incorporation dated June 11, 2019 was issued by the Registrar of Companies, Ahmedabad consequent upon conversion, recording the change in the name of the company to 'Kronox Lab Sciences Limited'.
The company manufactures High Purity Speciality Fine Chemicals for diversified end user industries. Its High Purity Speciality Fine Chemicals are used mainly as (i) reacting agents and raw material in the manufacturing of Active Pharmaceutical Ingredients (APIs); (ii) excipients in pharmaceutical formulations; (iii) reagents for scientific research and laboratory testing; (iv) ingredients in nutraceuticals formulations; (v) process intermediates and fermenting agents in biotech applications; (vi) ingredients in agrochemical formulations; (vii) ingredients in personal care products; (viii) refining agents in metal refineries; and (ix) ingredients in animal health products, amongst others. Its products are manufactured in accordance with industry standards like IP, BP, EP, JP, USP, FCC, LR, AR, GR and ACS in addition to custom manufacturing specifications, which differ from the industry standards, required by its customers in select cases. It manufactures High Purity Speciality Fine Chemicals of various grades in particle sizes ranging from 10 mesh to 100 mesh. Its focus on product development, diversity in product offerings, meeting quality standards and customer specifications and continuous process improvement has led to repeat orders from its customers over the years.
In addition to the manufacturing of products in accordance with various domestic and international standards, it also undertakes custom manufacturing to achieve high levels of purity, as specified by the client, having different purity levels than the prescribed industry standards. Custom manufacturing requires deep domain knowledge, expertise and understanding of the characteristics of each chemical and its compounds, including decreasing the level of existing impurities and the processes to be deployed to reach the desired level of purity. It has set up an in-house research, development and testing laboratory (RDT Laboratory) to develop new products and test its products against the specified industry standards or customer specifications. Its dedicated RDT Laboratory is located in Unit I with the objective to implement a performance-oriented approach with the help of advanced equipment and systems. Its RDT Laboratory is equipped with the necessary facilities to carry out tests required to develop the products.
Business area of the company
The company is a bulk manufacturer of high purity fine chemicals, in compliance with Reagent, Pharmacopoeia and various Food Grade standards, for the pharmaceutical, nutraceutical, veterinary, food, chemical analysis and other specialty markets.
Major events:
- 2008: Incorporation of the company.
- 2009: Commencement of manufacturing of High Purity Speciality Fine Chemicals at Unit I.
- 2010: Commenced export of products.
- 2011: The company expanded its Unit I for manufacturing of High Purity Speciality Fine Chemicals used in pharmaceutical and nutraceutical industries.
- 2011: The company started manufacturing High Purity Speciality Fine Chemicals to cater to the solar industries.
- 2014: Acquisition of land along with factory shed for Unit II.
- 2014: Receipt of FSSC 22000 certification from ISOQAR, UK for Unit I.
- 2015: Commencement of manufacturing operations at Unit II.
- 2015: Obtained FSSAI certification for manufacturing of food grade fine chemicals and ingredients.
- 2017: Receipt of ISO 14001: 2015 & OHSAS 18001:2007 certification in respect of Unit I.
- 2019: Started manufacturing of products at its Unit III.
- 2022: Acquisition of land along with factory shed for Unit I and Unit III.
- 2023: Acquisition of land for proposed Unit IV.
You have 46 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
